Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections by Dadachova, Ekaterina & Casadevall, Arturo
Hindawi Publishing Corporation
Interdisciplinary Perspectives on Infectious Diseases
Volume 2011, Article ID 830286, 11 pages
doi:10.1155/2011/830286
Review Article
Cryptococcusneoformans asa Model for
Radioimmunotherapy ofInfections
EkaterinaDadachova1,2 and ArturoCasadevall2,3
1Department of Nuclear Medicine, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461, USA
2Department of Microbiology and Immunology, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461, USA
3Department of Medicine, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461, USA
Correspondence should be addressed to Ekaterina Dadachova, edadacho@aecom.yu.edu
Received 3 February 2011; Accepted 14 March 2011
Academic Editor: Damian Krysan
Copyright © 2011 E. Dadachova and A. Casadevall. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
There is an obvious and urgent need for novel approaches to treat infectious diseases. The use of monoclonal antibodies in
therapyof infectious diseasesisnowexperiencing renewed interest. During thelast5 years radioimmunotherapy(RIT),amodality
previously developed only for cancer treatment, has been successfully adapted for the treatment of experimental fungal, bacterial,
and viral infections. As our model organism for studying the eﬃcacy, mechanisms, potential toxicity, and radioresistance to RIT,
as well as for comparison of RIT with the existing antimicrobial therapies we have chosen the encapsulated yeast Cryptococcus
neoformans (CN). The success of RIT approach in laboratory studies provides encouragement for feasibility of therapeutically
targeting microbes with labeled antibodies. In addition, the creation of “panantibodies” for RIT which would recognize antigens
shared by the whole class of pathogens such as fungi, for example, would facilitate the introduction of RIT into the clinic.
1.Introduction
The need for novel approaches to treat infectious diseases
at a time of increasing drug resistance and the emergence
of new pathogens is obvious and urgent. In recent decades
the problem of drug resistance has been compounded by
the emergence of many new infectious diseases like HIV.
Simultaneously the population of patients in whom current
antimicrobial therapies are not eﬀective because of their low
immune status is expanding and these include HIV-infected
individuals, cancer patients undergoing chemotherapy, and
recipients of organ transplants. In addition, there is a threat
of biological agents speciﬁcally engineered to be lethal even
in immunocompetent population.
This situation has renewed interest in using monoclonal
antibodies (mAbs) in therapy of infectious diseases [1].
Radioimmunotherapy (RIT) relies on antibodies to deliver
cytotoxic alpha- or beta radiation to tumor cells [2].
Radiolabeled mAb Zevalin and Bexxar are FDA approved
for untreated, refractory, and recurrent lymphomas. Several
years ago we introduced RIT into the realm of infectious
diseases, showing prolonged survival in mice systemically
infected with CN and treated after infection with radio-
labeled mAb speciﬁc for CN polysaccharide capsule [3].
During the last 7 years we have successfully adapted RIT
for the treatment of experimental fungal, bacterial, and viral
infections [4–7].
As our model organism for studying the eﬃcacy, mech-
anisms, potential toxicity, and radioresistance to RIT, as well
as for comparison of RIT with the existing antimicrobial
therapieswe havechosen theencapsulatedyeast Cryptococcus
neoformans (CN). CN has a worldwide distribution and
is a major fungal pathogen in immunocompromised hosts
responsible fornearlyonemillionseriousinfectionsannually
and 600,000 deaths [8]. Although the burden of disease
is disproportional in individuals with HIV infection, there
remains amajorriskforcryptococcosisintransplant patients
or individuals receiving immunosuppressive drugs, as well
as in patients with cancer, cirrhosis, and a variety of other
medical conditions. Its major virulence factors Cryptococcus
gattii has gained signiﬁcant public attention as the causative2 Interdisciplinary Perspectives on Infectious Diseases
agent of devastating pulmonary and central nervous system
infections in immunocompetent individuals principally in
the Northwestern USA and Canada.
Humoral immunity to CN has been extensively studied
by Casadevall’s laboratory for almost 20 years. Two mAbs
generated by his laboratory—18B7 mAb to CN capsular
polysaccharide antigen and 6D2 mAb to melanin—have
been used in clinical trials: trial of naked 18B7 in patients
with cryptococcal meningitis has been completed [9]; and
in collaboration with Dadachova 188-Rhenium-labeled 6D2
is currently undergoing trial in patients with metastatic
melanoma [10, 11]. CN provides an excellent model for
a chronic infection and advantages of the CN system
include (1) animal models including those for pulmonary,
meningeal, and latent infection; (2) the availability of very
well-characterized mAbs to CN that can be developed into
RIT agents; (3) the availability of anti-idiotypic reagents that
can be used to study the fate of labeled mAbs; (4) well-
understood pathogenesis of infection and immune response.
Here we will present the summary of the therapeutic
eﬃcacy of RIT of CN, its toxicity and potential for radiore-
sistance, radiobiological mechanisms, and comparison with
the standard antifungal therapy and we will outline future
perspective for developing RIT into the universal anti-fungal
modality in immunocompromised patients.
2.EfﬁcacyofRIT ofCN
We initially explored the potential eﬃcacy of RIT against
a systemic CN infection in partially complement deﬁcient
AJ/Cr mice (National Cancer Institute, Frederick, MD). The
results discussed below are published in [3]. We radiolabeled
CN polysaccharide capsule-speciﬁc mAb 18B7 with alpha-
particle emitting 213-Bismuth (213Bi) or the beta-particle
emitting 188-Rhenium (188Re). Mice treated with radiola-
beled 18B7 mAb lived signiﬁcantly longer than mice given
irrelevant labeled IgG1 or PBS. We used a labeled irrelevant
mAb (213Bi- or 188Re-labeled IgG1 MOPC21) to control for
the possibility that Fc receptor binding by the radiolabeled
IgG to phagocytes at the site of infection might result in
nonspeciﬁc killing of CN cells. Remarkably, 60% of mice
in 100μCi 213Bi group were alive on day 75 after therapy
(P<. 05). In the 188Re group, 40% and 20% of animals
were alive after treatment with 100 (P<. 005) and 50μCi
(P<. 05) 188Re-18B7, respectively, while mice in control
groups succumbed to infection on days 35–40 (Figures 1(a)
and 1(b)). Mice infected with CN and given RIT had sig-
nificantly reduced fungal burden in lungs and brains 48h
after treatment when compared to control groups. While
there was no diﬀerence in the reduction of the fungal burden
in the lungs between the groups that received 50 and 100μCi
188Re-18B7, treatment with 200μCi 188Re-18B7 signiﬁcantly
lowered lung CFUs relative to the lower activities (P<. 05).
Hence, administration ofa radiolabeled antibody to CN pol-
ysaccharide prolonged survival and reduced organ fungal
burden in infected mice.
When the RIT dose dependence was investigated, sur-
vival of A/JCr mice was dose dependent for both 213Bi
and 188Re radioisotopes: while 50μCi 213Bi-18B7 produced
no therapeutic eﬀect, both the 100 and 200μCi doses
prolonged animal survival [3]. Interestingly, the 200μCi
213Bi-18B7 dose was less eﬃcient, possibly because it may
have approached the MTA (maximum tolerated activity) for
this particular combination of antibody and radioisotope.
L a t e rw ee v a l u a t e dt h ee ﬃcacy of RIT against fungal
bioﬁlms. The results discussed below are published in [12].
The use of indwelling medical devices—pacemakers, pros-
thetic joints, and catheters—is rapidly growing and is often
complicated by infections with bioﬁlm-forming microbes
that are resistant to antimicrobial agents and host defense
mechanisms. We investigated the use of polysaccharide-
speciﬁc mAbsas delivery vehiclesfortargeting C. neoformans
bioﬁlms with 213Bi. 213Bi-18B7 mAb (IgG1) penetrated
cryptococcal bioﬁlms, as shown by confocal microscopy
and caused a 50% reduction in bioﬁlm metabolic activity
(Figure 1(c) left panel). In contrast, when the IgM mAb
13F1 labeled with 213Bi was used—there was no penetration
of the fungal bioﬁlm and no damage. Unlabeled 18B7,
213Bi-labeled nonspeciﬁc mAbs, and gamma and beta types
of radiation (Figure 1(c) r i g h tp a n e l )d i dn o th a v ea n
eﬀect on bioﬁlms. The lack of eﬃcacy of gamma and beta
radiation probably reﬂects the radioprotective properties of
polysaccharide bioﬁlm matrix. Our results indicate that CN
bioﬁlms are susceptible to treatment with antibody-targeted
alpha radiation, suggesting that RIT could provide a novel
option for the prevention or treatment of microbial bioﬁlms
on indwelling medical devices.
3.ToxicityofRIT ofCN
WhileitwasknownfromthecancerRITdatathattheplatelet
counts nadir usually occurred 1 week after radiolabeled
antibody administration to tumor-bearing mice [14, 15]—
there was no information about possible toxic eﬀects of
RIT in infected animals. In our studies of RIT for murine
cryptococcosis we evaluated the hematological toxicity of
radiolabeled antibodies in mice by platelet counts [13]. In
AJ/Cr mice systemically infected with CN no changes in
platelet counts were observed for the doses of up to 150μCi
213Bi- or 188Re-labeled mAbs (Figure 2(a)) attesting to the
lackofthehematologictoxicityinthisrangewhilemicegiven
200 and 250μCi died by day 7 posttreatment [13].
We also considered the possibility that RIT of CN
infection may promote lung ﬁbrosis in treated animals.
Lungs are the target organ for CN infection and it is
k n o w nf r o mc a n c e rﬁ e l dt h a tl u n g sc a nd e v e l o pﬁ b r o s i s
several months after treatment with external beam radiation
therapy [16]. To evaluate this potential complication we
used a pulmonary model of CN where mice are infected
intratracheally (IT). In this model, CN is mostly localized
to the lungs on day 5 after infection, and as a result up
to 10% of the injected dose/g was found in the lungs at
24h after treatment with radiolabeled MAbs, versus 1.5%
of the injected dose/g in the lungs of non-infected mice [3].
The results described below are published in [13]. BALB/c
mice were infected IT with 106 CN cells, and on day 5 afterInterdisciplinary Perspectives on Infectious Diseases 3
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Figure 1: Eﬃcacy of RIT of CN with 213Bi- and 188Re- labeled mAbs: (a, b) Kaplan-Meier survival curves for A/JCr mice infected IV with
105 C. neoformans cells 24hr prior to treatment with 50–200μCi 188Re- (a) or 213Bi-labeled (b) mAbs.Animalsinjected with PBS (phosphate
buﬀered saline) or 50μg “cold” 18B7 served as controls; (c) treatment of CN bioﬁlms in vitro with 213Bi- (left panel ) or 188Re- (right panel)
labeled 18B7 mAb; adapted from [3, 12].
infection they were treated with 50–200μCi 213Bi- or 188Re-
labeled mAbs or left untreated. All mice were subsequently
maintained on ﬂuconazole to control infection (10mg/kg
in their drinking water). After 5 months, the mice were
sacriﬁced, and their lungs were removed, ﬁxed with buﬀered
formalin,sectioned,stained withhematoxylinand eosin,and
analyzed histologically. There was no evidence of radiation
ﬁbrosis in the lungs of radiation-treated mice (Figures 2(c)
and 2(d)) compared to control animals (Figure 2(b)). This
lack of hematological and pulmonary toxicity can be
explained by the very speciﬁc targeting of radiolabeled
antibodies to the microbes/infected cells. In fact, one of the
advantages of using RIT against infections as opposed to
cancer is that, in contrast to tumor cells, cells expressing
microbial antigens are antigenically very diﬀerent from host
tissues and thus provide the potential for exquisitespeciﬁcity
and low cross-reactivity. It should also be noted that in all
our studies the radiolabeled mAbs were administered ip, and
ip administration of the radiolabeled mAbs was reported
to be better tolerated than iv route [17]. In addition, when
using a radioactive therapy in patients there is always a
concern of long-term eﬀects such as neoplasms arising from
radiation-induced mutations. However, this risk should be
extremely low after short-term exposure and would likely4 Interdisciplinary Perspectives on Infectious Diseases
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Figure 2: Toxicity of RIT in micewith CN infections.(a)Platelet counts in RIT-treated mice. CN-infected A/JCr micereceived various doses
of 213Bi-18B7. A “0” indicates infected nontreated mice. Mice treated with 200 and 250μCi 213Bi-18B7 died by day 7 posttreatment; (b–d)
micrographs of hematoxylin-and-eosin-stained lungs from BALB/c mice infected IT with CN and treated with radiolabeled mAbs. Mice
were sacriﬁced 5 months after RIT: (b) infected control group (no RIT); (c) 200μCi 213Bi-18B7; (d) 200μCi 188Re-18B7; adapted from [13].
be outweighed by the beneﬁts of treating or preventing
infections. Nevertheless, the application of RIT to infectious
diseases willrequireoptimizationofthedosetoascertain and
minimize toxic eﬀects.
4.RIT andRadiationResistance
The emergence of radiation-resistant CN cells would be a
concern for multiple RIT administrations, and therapeutic
outcome. Thus, we evaluated susceptibility of CN cells
isolated from RIT-treated mice to RIT in vitro. The results
discussed below are published in [18]. To generate RIT-
treated CN cells, AJ/Cr mice were infected IV with 5 ×
104 cells and 24hrs later treated with either 150μCi 188Re-
18B7 or 125μCi 213Bi-18B7 or left untreated. The surviving
mice were sacriﬁced, their lungs homogenized and plated on
SAB agar; isolated colonies were grown overnight in SAB
broth. To assess radiosensitivity of the cells in vitro, cells
from ATCC (CNnaive), recovered from untreated AJ/Cr mice
(CNpassaged) and recovered from mice given 188Re-18B7 mAb
(CNRe RIT)o r213Bi-18B7 mAb (CNBi RIT) were treated with
188Re- or 213Bi-18B7 mAb as in [3]. Naive, passaged, or RIT
pretreated cells were equally radiosensitive to both 188Re and
213Bi attesting to the absence of in vitro radioresistance of
RIT-pretreated cells (Figures 3(a) and 3(b)).
To evaluate the possibility that RIT might select for CN
cells resistant to radiation in vivo, we infected AJ/Cr mice
with CNRe-RIT,C N Bi-RIT and CNnaive. Infected mice were
treated with 150μCi 188Re-18B7or 125μCi 213Bi-18B724hrs
after iv infection, then monitored for survival and weight
loss. Lethality in mice infected with CNRe-RIT or CNBi-RIT
was the same as in mice infected with CNnaive (P>. 05)
(Figure 3(c)). Survival of mice treated with 213Bi-18B7 mAb
was longer (P = .04) than with 188Re-18B7 (Figure 3(c)),
probably due to the higher killing power of alpha particles
from 213Bi, compared to electrons from 188Re. Overall, the
treatment of CN with particulate radiation leads to loss of
the ability of the cells to replicate [3, 19], which would
explain the absence of radiation-resistant phenotypes after
RIT. The residual cells which replicate after RIT most likely
were protected from radiolabeled antibodies by a bioﬁlm, an
abscess, or a host cell.Interdisciplinary Perspectives on Infectious Diseases 5
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Figure 3: Investigation of possible resistance to RIT of CN in vivo and in vitro: (a) in vitro killing of CN cells with 188Re-18B7 mAb. Each
sample contained 105 fungal cells; (b) in vitro killing of CN cells with 213Bi-18B7 mAb. Each sample contained 105 fungal cells; (c) median
survival of AJ/Cr mice infected IV with 5 × 104 CN and treated 24hrs later with 150μCi 188Re-18B7 or 125 μCi 213Bi-18B7 mAb. CNnaive:
cells from ATCC; CNpassaged: cells recovered from untreated AJ/Cr mice; CNRe RIT: cells recovered from mice treated with 188Re-18B7 mAb;
CNBi RIT: cells recovered from mice treated with 213Bi-18B7 mAb; Re RIT/ CNnaive: mice infected with CNnaive and treated with 188Re-18B7;
Bi RIT/ CNnaive: mice infected with CNnaive and treated with 213Bi-18B7; Re RIT/ CNRe RIT: mice infected with CNRe RIT and treated with
188Re-18B7; Bi RIT/ CNBi RIT: mice infected with CNBi RIT and treated with 213Bi-18B7; adapted from [18].
5.RadiobiologicalMechanisms ofRIT ofCN
Given that RIT of infectious diseases is a relatively young
ﬁeld,themechanisms bywhich RITis eﬀectiveare uncertain.
Even in oncology where the antineoplastic eﬀects of RIT
have been investigated for more than 25 years the cytotoxic
mechanisms are still debated. The major radiobiological
mechanisms of cancer RIT are considered to be “direct
hit” (when a cell is killed by radiation emanating from the
same cell) and “cross-ﬁre” eﬀects (when a cell is killed by
radiation emanating from a distant cell), both of which can
promote apoptosis and cell cycle redistribution [20]. We6 Interdisciplinary Perspectives on Infectious Diseases
investigated the radiofungicidal eﬀects of external gamma
radiation and 213Bi- or 188Re-labeled mAbs on CN cells
by evaluating the eﬀect of radiofungicidal doses on cell
membrane permeability, induction of apoptosis, and cellular
metabolism. The results discussed below are published in
[19].
An increased membrane permeability to the dye pro-
pidium iodide (PI) is considered to be a marker of cell
death since viable cells with intact membranes are able
to exclude the dye. Internalized PI binds to nucleic acids
and undergoes a large increase in ﬂuorescence [22]. PI
staining correlates with loss of colony forming units (CFUs)
in a variety of microorganisms including CN treated with
antifungal agents [23]. The permeability increased with time
between 1 and 3hr following gamma irradiation, indicating
that it was probably secondary to cell death, not a cause
of death (Figure 4(a)). It seems likely that the cells in this
20% of the population are metabolically “dead” and unable
to maintain membrane integrity. Cells stained 3hr after
irradiation showed dose-dependent PI staining up to 300Gy
(25% PI positive), with a decrease to 10% PI positive at
thehighest dose(Figure 4(a)). This observation suggeststhat
membrane damage is not the primary lethal event,as 80% of
the cells had lost the ability to replicate at these doses. The
decrease in PI positive cells at the highest dose may be due to
radioprotectiveeﬀectsfrom the shed capsule [24]. Treatment
of CN with 188Re-18B7 did not make the cells PI permeable
(Figure 4(b)). Treatment with 213Bi-18B7 mAb led to about
7% of the cells becoming PI permeable, at a dose that caused
80% loss of CFUs (Figure 4(c)).
Fungalcellsundergoapoptosisorprogrammedcelldeath
[25]. In the same paper [19], we investigated whether
radiation increased levels of fungal caspase, as measured
by FLICA (ﬂuorochrome labeled inhibitor of caspase)
binding—a membrane permeable substrate that binds to
caspases induced during early apoptosis. Earlier, we vali-
dated this technique for use with CN by comparing the
FLICA results with those obtained using APO-BrdU TUNEL
apoptosis detection kit [21]. Gamma-irradiated cells were
about 10% FLICA positive at 3hr (Figure 4(d))w h i l e2 0a n d
5% of CN cells exposed to 188Re-18B7 or 213Bi-18B7 mAbs,
respectively, became FLICA positive (Figures 4(e) and 4(f)).
The number of FLICA positive 213Bi-18B7 mAb-treated
cells staining was higher at 17hrs than at 3hrs, indicating
an ongoing process of apoptosis induction. Apoptosis is
a dynamic process, and cells pass through several stages,
not staying at any one stage for a long time. The decrease
seen at 21hrs for the gamma-radiation treated cells may
indicate that at that time the cells have ﬁnished the stage
of apoptosis during which the caspases are available to bind
the ﬂuorescent inhibitors. This is in contrast to the increase
withtime observedfor 213Bi-18B7mAb treated cellsand may
reﬂect a diﬀerence in pathways of cell death induced by the
diﬀerent forms of radioactivity. We concluded that gamma,
beta,and alpharadiation aﬀectedcellsvia diﬀerentpathways.
Gammaradiationhadmoreeﬀectonthecellmembranethan
213Bi-18B7 or 188Re-18B7. All forms of radiation stimulated
apoptosis-like cell death with gamma radiation and 188Re-
18B7 mAb having more pronounced eﬀect than 213Bi-18B7
mAb. 213Bi-18B7 mAb delivered “directly” decreased the
metabolic activity of fungal cells, while the other forms of
radiation did not. Clonogenic survival proved to be the
most practical measure of assessing RIT eﬃcacy, by virtue
of reﬂecting a combination of multiple mechanisms leading
to fungal celldeath. Cells which are alive after RIT treatment,
butnotreplicating,may ormay notcontributetothedisease.
To elucidate the contribution of “direct hit” and “cross-
ﬁre” eﬀectsto RITofCN we comparedthe fungicidalactivity
of a mAb radiolabeled with 213Bi or 188Re—isotopes with
diﬀerent emission ranges in tissue −50–80μmf o r213Bi
versus10mm for 188Re. In cancer RIT, 213Biis assumed tokill
by “direct hit”, while 188Re, through “cross-ﬁre”. In principle,
every cell with bound radiolabeled mAb molecules can be
killed by a “direct hit” and simultaneously serve as a source
of “cross-ﬁre” radiation. By measuring the killing of the
cells in RIT and in “cross-ﬁre” experiments, we can calculate
contributionof“directhit”towardscellkillingbysubtracting
percentage of cells killed by “cross-ﬁre” from percentage of
cells killed by RIT. The results discussed below are published
in [21].To observe“cross-ﬁre” we had to ensure that thecells
that served as the sources of “cross-ﬁre” radiation could not
be killed themselves by “direct hit”. Consequently, we used
heat killed CN cells as the sources of “cross-ﬁre” radiation.
Experiments with 213Bi-18B7 showed that although most
fungal cells were killed by “direct hit”, “cross-ﬁre” eﬀect also
contributed to the fungicidal eﬀect of RIT (Figure 4(g)). No
killing of CN cells by unlabeled mAb 18B7 was observed.
For 188Re-18B7“cross-ﬁre” eﬀect was responsible for most of
CN killing (Figure 4(h)). This system permits experiments
to elucidate precise mechanisms of cell killing in RIT that
have not been performed either for microbial or cancer
cells. In RIT targeting of cancer cells the antibody is often
internalized after binding, adding signiﬁcant complexity
to the experiment. One of the advantages of the CN
system is that the capsule is outside the cell wall and that
antibody isnotinternalized, thusallowing explorationofthis
fundamental problemin radiobiology. One minor limitation
of this system is that the antibody could be internalized by
phagocytes that ingest the antibody-labeled CN. Knowledge
of the radiobiological mechanisms of RIT will allow creation
of more eﬀective protocols for RIT of opportunistic fungal
infections.
6.Comparisonof RITof CNwithStandard
AntifungalTreatment
As an important step towards bringing RITof fungal diseases
into the clinic, we compared the eﬃcacy of RIT versus
amphotericin against systemic experimental CN infection.
The results discussed below are published in [26]. We
hypothesized that 18B7 mAb radiolabeled with 213Bi or with
188Rewouldbeabletokillbothmelanized andnonmelanized
CN cells in vivo better than standard antifungal therapy.
We also investigated whether the combination of RIT and
amphotericin treatment produced diﬀerent results from
either therapy alone. For this melanized and nonmelanized
24067 CN cells were incubated with increasing activitiesInterdisciplinary Perspectives on Infectious Diseases 7
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Figure 4: Contribution of diﬀerent radiobiological eﬀects to RIT of CN with 213Bi-18B7 and 188Re-18B7 mAbs. (a–c) show CFUs and PI
permeability for:(a)external gammaradiation;(b) 188Re-18B7; (c) 213Bi-18B7.(d–f) showCFUs andapoptosis levels by FLICA: (d) external
gamma radiation; (e) 188Re-18B7; (f) 213Bi-18B7. (g–h) show contribution of “cross-ﬁre” and “direct hit” towards killing of CN cells: (g)
“cross-ﬁre” and “direct hit” for 213Bi-18B7; (h) “cross-ﬁre” and “direct hit” for 188Re-18B7. The contribution of “direct hit” towards cell
killing was calculated by subtracting percentage of cells killed by “cross-ﬁre” from percentage of cells killed by RIT; adapted from[19, 21].
of 188Re- and 213Bi-18B7 mAb. Incubation of melanized
and nonmelanized cells with 188Re- or 213Bi-18B7 mAb
killed 90% of the cells and delivered cellular radiation
doses of 0.1 krad for 188Re-18B7 and 0.04 krad for 213Bi-
18B7 (Figures 5(a) and 5(b)). 213Bi or 188Re conjugated
to the irrelevant isotype-matching antibody MOPC killed
neither type of cell (Figures 5(a) and 5(b)). The diﬀer-
ence in susceptibility of melanized and nonmelanized cells
to antibody-delivered radiation became obvious when we
attempted to achieve 99.9% elimination of cells. Sixteen
μCi (0.8 krad dose) of 188Re-18B7 mAb eliminated 99.9%
of nonmelanized cells, while that degree of cell killing was
not achieved for melanized cells in the investigated range
of activity. 213Bi-18B7 mAb killed 99.7% of nonmelanized
cells with 0.4μCi (0.17 krad dose) but again that level
of cell killing was not observed for melanized cells. As8 Interdisciplinary Perspectives on Infectious Diseases
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Figure 5:ComparisonofRIT andamphotericineﬃcacy towards nonmelanizedand melanizedCN in vitro and in vivo. (a–c) In vitro killing
and dosimetry of melanized and nonmelanized CN cells treated with: (a) 188Re-labeled 8B7 and control isotype-matching MOPC21 mAbs;
(b) 213Bi-labeled 18B7 and control MOPC21 mAbs; (c) amphotericin B; mel:melanized CN cells; non-mel:nonmelanized CN cells; (d,e)
CFUs in the lungs and brains of mice infected with nonmelanized or melanized CN. AJ/Cr mice were infected IV with 3 × 105 CN cells
and 24hr later either given 100μCi 213Bi-18B7 RIT or amphotericin B at 1μg / gb o d yw e i g h to nD a y s1 ,2 ,a n d3a f t e ri n f e c t i o no rc o m b i n e d
treatment or left untreated: (d) nonmelanized CN; (e) melanized CN. Detection limit of the method was 50 CFUs. No CFUs were found in
the brains and lungs of mice infected with melanized CN cells and treated with RIT which are presented in the graph as 40 CFUs/organ; (f)
CFUs in the brain and lungs of mice infected with 3 × 105 melanized (M) or nonmelanized (NM) CN cells and treated with amphotericin
Ba t1μg/g body weight for 14 days. Mice were sacriﬁced at days 7 and 14 posttreatment; adapted from [26].Interdisciplinary Perspectives on Infectious Diseases 9
approximately 10 times less 213Bi than 188Re radioactivity
was required to eliminate the bulk of either melanized
or nonmelanized cells we selected 213Bi-mAbs for in vivo
comparison with amphotericin. One μg/mL amphotericin
reduced CN CFUs by more than two log units (Figure 5(c)).
Considering published MIC for melanized 24067 CN
being higher than for nonmelanized; we selected a dose
of 1μg/gram of mouse body weight (∼17μg/mouse),
allowing a transient blood concentration of 8.5μg/mL, for
in vivo experiments.
Subsequently we compared the eﬃcacy of RIT alone
to that of amphotericin and combined therapy in vivo.
AJCr mice were infected iv with 3 × 105 melanized or
nonmelanized CN cells. One day after infection mice were
divided into groups of 5 that were either untreated; or
given ip 100μCi 213Bi-18B7; or treated at 24, 48, and
7 2 hw i t ha m p h o t e r i c i na sd e o x y c h o l a t ea t1 μg/g body
weight; or received both treatments. Mice were monitored
for survival for 60 days. Analysis of lungs and brains at
60 days after infection showed that amphotericin did not
signiﬁcantly decrease CFUs in the lungs and the brains in
either nonmelanized (Figure 5(d)) or melanized CN groups
(Figure 5(e))( P>. 05). RIT had signiﬁcantly decreased
fungal burdens compared to untreated or amphotericin-
treated mice (P   .05). In fact, RIT-treated nonmelanized
CN group almost completely cleared fungus from the brain
(thelowerlimitofdetectionwas50CFUs),while RIT-treated
melanized CN group almost completelycleared the infection
from both brain and lungs.
Our most important observation is that RIT was more
eﬀective in reducing fungal burden in lungs and brains than
amphotericin at a high dose of 1μg/g, with most RIT-treated
mice almost completely clearing the infection. The inability
of amphotericin to reduce the fungal burden in the organs
of partially complement deﬁcient AJCr mice after 3 days of
treatment was explained by the follow-up study with a trend
towards reduction of CFUs in brains and lungs manifesting
itself only on the 14th day of treatment (Figure 5(f)).
These observations are in concert with literature showing
that even in intact robust mice as CD-1 or Balb/c ampho-
tericin as deoxycholate was also only able to produce 1–
1.5 log reduction in CFUs and all mice died around day
24 [27, 28]. It is also in concert with the data from clinical
studies showing that a short course of amphotericin does
not sterilize cerebrospinal ﬂuid or blood, and that the rate
of sterilization correlates with survival [29]. Our obser-
vation underlines the advantages of RIT which produces
microbicidal eﬀects in vivo just after one injection when
compared to prolonged treatment with amphotericin. When
combined RIT and amphotericin treatment was used—
a complex picture emerged depending on the melaniza-
tion status of infection. Combination treatment was more
eﬀective than amphotericin alone for both nonmelanized
and melanized CN groups. In melanized CN group the
combination treatment was less eﬀective than RIT which
could be due to inﬂammation and renal toxicities associated
with amphotericin at this dose in mice. Interestingly, for
nonmelanized CN the combination treatment did produce
some synergy in reducing CFUs in the lungs. It is possible
to suggest that if RIT is administered much later during
the course of treatment with amphotericin; some synergistic
eﬀects could be observed.
7.Conclusions
The success of RIT of CN in laboratory studies combined
with earlier nuclear medicine experience on preclinical and
clinical studies showing the utility of radiolabeled organism-
speciﬁc antibodies for imaging of infections (reviewed in
[30]) provides encouragement for feasibility of therapeu-
tically targeting microbes with labeled antibodies. In fact,
the ability of a speciﬁc antibody to localize to a site of
infection indicates the feasibility of using the antibody-
antigen interaction to deliver microbicidal radiation to
sites of infection, which in turn provides strong support
for the potential usefulness of this technique as a broad
antimicrobial strategy. As microbial cells are foreign to the
human body; they contain antigens that are not expressed by
human tissues and this provide a major contrast to cancer
RIT since tumor-associated antigens are also expressed on
normal tissues. Consequently, the theoretical therapeutic
index of RIT for microbial diseases should be signiﬁcantly
higher than for neoplastic diseases. This exquisite speciﬁcity
promises exclusivity of targeting which should translate into
high eﬃcacy of treatment and low toxicity. It might be
possible to create a so-called “pan-antibody” which would
recognize an antigen shared by a particular class of human
pathogens such as fungi, for example. Example of such
“panantibodies” is a mAb 6D2 initially developed against
fungal melanin which also binds to synthetic, invertebrate
(cuttleﬁsh), murine and human melanin [10]; mAbs to heat
shock protein 60 (HSP60) [31] and beta-glucans [32]w h i c h
bind to all major human pathogenic fungi. The experiments
on developing RIT with such panantibodies are currently
ongoing in our laboratories (Bryan et al. unpublished
observations). The availability of such antibodies would
eliminate the necessity of having antibodies speciﬁc for each
particular microorganism and would enormously enhance
the development of RIT of infectious diseases.
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